Technology ID
TAB-5049
A Novel Strategy to Produce 6-cys Proteins Based on Pfs230D1 Domain Fusions
E-Numbers
E-086-2023-0
Lead Inventor
Duffy, Patrick
Lead IC
NIAID
Co-Inventors
Renn, Jonathan
ICs
NIAID
Applications
Vaccines
Therapeutics
Research Materials
Therapeutic Areas
Infectious Disease
Immunology
Development Stages
Pre-clinical (in vivo)
Research Products
Sequences
The Plasmodium parasite has a complex lifecycle during human infection and in the mosquito vector. Most advanced malaria vaccine candidates can confer only partial, short-term protection in malaria-endemic areas. A means of breaking the transmission of malaria to subsequent individuals could prevent a significant amount of human disease.
The primary embodiments of this technology are novel compositions of matter that produce enhanced transmission-blocking responses over current transmission blocking vaccines:
- The inventors designed fusion protein sequences incorporating Pfs230 domain1 (Pfs230D1) at the N-terminus with additional Plasmodium 6-cys domains downstream.
- The artificial immunogens retained structured transmission blocking epitopes.
This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.
Commercial Applications
- This technology could be used alone or in combination with existing malaria vaccines.
Competitive Advantages
- The immunogens were used in small animal vaccination studies where the Pfs230D1-Pfs48/45D3, Pfs230D1-Pfs230D9, Pfs230D1-3 fusions prompted greater functional serum activity compared to Pfs230D1 alone.
- Pfs230D1 or its ortholog Pvs230D1 enabled expression of other downstream domains of Pvs230 or Pv48/45D3 another malaria species that causes human disease.
Licensing Contact: